Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elan, Royalty Pharma deal

Royalty Pharma issued its formal offer to acquire Elan for $11.25 per share in cash, or about $5.7 billion. Royalty Pharma said that

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE